AdaptHealth Corp. Announces Third Quarter 2022 Results and Updates 2022 Outlook

Rhea-AI Summary

AdaptHealth Corp. (NASDAQ: AHCO) reported record net revenue of $756.5 million for Q3 2022, up 15.8% from $653.3 million in Q3 2021. However, net income dropped to $16.1 million ($0.11 per share) from $58.1 million ($0.20 per share) year-over-year. Adjusted EBITDA increased slightly to $160.2 million, while cash flow from operations rose significantly to $107.0 million. The company updated its fiscal year 2022 guidance, projecting net revenue between $2.950 billion and $3.010 billion, reflecting strong demand in the healthcare-at-home market.

Positive

• Record net revenue of $756.5 million for Q3 2022, a 15.8% increase from Q3 2021.
• Cash flow from operations increased to $107.0 million compared to $27.1 million in Q3 2021.
• Adjusted EBITDA rose to $160.2 million, a 2.5% increase year-over-year.
• Updated guidance for fiscal year 2022 projects net revenue between $2.950 billion and $3.010 billion.

Negative

• Net income decreased to $16.1 million compared to $58.1 million in the same quarter of 2021.

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the third quarter ended September 30, 2022.

Third Quarter Results and Highlights

• AdaptHealth delivered record net revenue of $756.5 million for the third quarter of 2022 compared to $653.3 million in the third quarter of 2021, an increase of 15.8%.
• Net income attributable to AdaptHealth Corp. was $16.1 million, or $0.11 per diluted share, compared to $58.1 million, or $0.20 per diluted share, in the third quarter of 2021.
• Non-acquired net revenue for the third quarter increased 6.1% over the third quarter of 2021.
• Sleep rental revenue continued to show strong sequential growth with further improvement in the supply of PAP machines relative to recent quarters.
• Adjusted EBITDA was $160.2 million, compared to $156.3 million in the third quarter of 2021, an increase of 2.5%.
• Cash flow from operations was $107.0 million, compared to $27.1 million in the third quarter of 2021.
• The Company repurchased $10.6 million of its common stock in the open market during the quarter using available cash, pursuant to the previously-announced share repurchase authorization.

Guidance Updated for Fiscal Year 2022

The Company is updating its previously issued financial guidance for fiscal year 2022, as follows:

• Net revenue of $2.950 billion to $3.010 billion (previously $2.840 billion to $3.040 billion);
• Adjusted EBITDA of $620 million to $650 million (previously $615 million to $675 million); and
• Total capital expenditures representing 10-12% of net revenue (previously 9-11%).

Guidance for fiscal year 2022 does not include any contribution from acquisitions that have not yet closed.

Management Commentary

Steve Griggs, Chief Executive Officer, commented, “We delivered another solid quarter as we continued to capitalize on strong demand in our HME and Sleep product lines with CPAP patient set-ups at or near record levels each month of the quarter, and our diabetes product line once again posting double-digit growth. Additionally, our operational excellence initiatives continued to partially offset general inflationary pressures and higher labor costs. As a result, we were pleased to see sequential margin expansion in the third quarter and expect further improvement in the fourth quarter. This strong performance demonstrates the resilience of our business and confirms confidence in our ability to achieve the 2025 goals we set out at our Capital Markets Day.”

Josh Parnes, President, said, “The healthcare marketplace continues to move aggressively to the home environment, and we are positioning AdaptHealth to lead this shift with our technology-enabled, patient-first integrated care model. As we look ahead, our team remains deeply committed to deliver on our mission of helping the approximately 3.9 million patients we serve to live their healthiest lives at home while reducing healthcare costs and unlocking AdaptHealth’s earnings and growth potential.”

Conference Call

Management will host a conference call at 8:30 am ET today to discuss the results and business activities. Interested parties may participate in the call by dialing:

• (877) 407-6176 (Domestic) or
• (201) 689-8451 (International)

Webcast registration: Click Here

Following the live call, a replay will be available for six months on the Company's website, www.adapthealth.com under "Investor Relations."

About AdaptHealth Corp.

AdaptHealth is a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company provides a full suite of medical products and solutions designed to help patients manage chronic conditions in the home, adapt to challenges in their activities of daily living, and thrive. Product and service offerings include (i) sleep therapy equipment, supplies, and related services (including CPAP and bi PAP services) to individuals suffering from obstructive sleep apnea, (ii) medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors and insulin pumps), (iii) HME to patients discharged from acute care and other facilities, (iv) oxygen and related chronic therapy services in the home, and (v) other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs. The Company is proud to partner with an extensive and highly diversified network of referral sources, including acute care hospitals, sleep labs, pulmonologists, skilled nursing facilities, and clinics. AdaptHealth services beneficiaries of Medicare, Medicaid, and commercial insurance payors, reaching approximately 3.9 million patients annually in all 50 states through its network of approximately 750 locations in 47 states.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations and the Company’s acquisition pipeline. These statements are based on various assumptions and on the current expectations of AdaptHealth management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the Company.

These forward-looking statements are subject to a number of risks and uncertainties, including the outcome of judicial and administrative proceedings to which the Company may become a party or governmental investigations to which the Company may become subject that could interrupt or limit the Company’s operations, result in adverse judgments, settlements or fines and create negative publicity; changes in the Company’s customers’ preferences, prospects and the competitive conditions prevailing in the healthcare sector; and the impact of the coronavirus (COVID-19) pandemic and the Company’s response to it. A further description of such risks and uncertainties can be found in the Company’s filings with the Securities and Exchange Commission. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company presently knows or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the Company’s expectations, plans or forecasts of future events and views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company’s assessments to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Use of Non-GAAP Financial Information and Financial Guidance

This release contains non-GAAP financial guidance, which is adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis. These non-GAAP items are adjusted after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods.

The Company uses EBITDA and Adjusted EBITDA, which are financial measures that are not prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, to analyze its financial results and believes that they are useful to investors, as a supplement to U.S. GAAP measures.

The Company believes Adjusted EBITDA is useful to investors in evaluating the Company’s financial performance. The Company uses this metric as the profitability measure in its incentive compensation plans that have a profitability component and to evaluate acquisition opportunities, where it is most often used for purposes of contingent consideration arrangements.

EBITDA and Adjusted EBITDA should not be considered as measures of financial performance under U.S. GAAP, and the items excluded from EBITDA and Adjusted EBITDA are significant components in understanding and assessing financial performance. Accordingly, these key business metrics have limitations as an analytical tool. They should not be considered as an alternative to net income or any other performance measures derived in accordance with U.S. GAAP or as an alternative to cash flows from operating activities as a measure of the Company’s liquidity.

There is no reliable or reasonably estimable comparable GAAP measure for the Company’s non-GAAP financial guidance because the Company is not able to reliably predict the impact of certain items, including equity-based compensation expense, transaction costs, changes in fair value of the warrant liability, and other non-recurring items of expense or income in full year 2022. As a result, reconciliation of these non-GAAP measures to the most directly comparable GAAP measure is not available without unreasonable effort. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on the Company’s future GAAP results.

In addition, the Company’s non-GAAP financial guidance in this release excludes the impact of any potential additional future strategic acquisitions and any specified items that have not yet been identified and quantified. The guidance also excludes macro-economic effects due to the COVID-19 pandemic that are not yet quantifiable. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release.

ADAPTHEALTH CORP.
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands)							September 30, 2022			December 31, 2021
Assets
Current assets:
Cash and cash equivalents						$	110,738		$	149,627
Accounts receivable							358,341			359,896
Inventory							125,362			123,095
Prepaid and other current assets							37,490			37,440
Total current assets							631,931			670,058
Equipment and other fixed assets, net							473,056			398,577
Operating lease right-of-use assets							128,635			147,760
Goodwill							3,524,999			3,512,567
Identifiable intangible assets, net							172,772			202,231
Other assets							20,453			15,098
Deferred tax assets							286,135			304,193
Total Assets						$	5,237,981		$	5,250,484
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued expenses						$	346,920		$	358,384
Current portion of finance lease obligations							2,695			15,446
Current portion of operating lease obligations							28,769			31,418
Current portion of long-term debt							30,000			20,000
Contract liabilities							31,605			31,370
Other liabilities							26,938			43,194
Total current liabilities							466,927			499,812
Long-term debt, less current portion							2,162,088			2,183,552
Operating lease obligations, less current portion							103,859			120,180
Other long-term liabilities							306,641			322,487
Warrant liability							38,516			57,764
Total Liabilities							3,078,031			3,183,795
Total Stockholders' Equity							2,159,950			2,066,689
Total Liabilities and Stockholders' Equity						$	5,237,981		$	5,250,484

ADAPTHEALTH CORP.
Consolidated Statements of Operations (Unaudited)
			Three Months Ended							Nine Months Ended
(in thousands, except per share data)			September 30,							September 30,
			2022			2021				2022				2021
Net revenue			$	756,495		$	653,293			$	2,190,312			$	1,752,429
Costs and expenses:
Cost of net revenue				646,714			529,887				1,853,847				1,417,305
General and administrative expenses				40,681			33,006				124,673				132,584
Depreciation and amortization, excluding patient equipment depreciation				16,151			14,690				48,113				46,014
Total costs and expenses				703,546			577,583				2,026,633				1,595,903
Operating income				52,949			75,710				163,679				156,526
Interest expense, net				28,521			24,252				78,905				69,584
Change in fair value of warrant liability				1,364			(16,737	)			(17,145	)			(57,359	)
Change in fair value of contingent consideration common shares liability				—			(10,006	)			—				(34,050	)
Loss on extinguishment of debt				—			8,240				—				20,189
Other loss (income), net				257			(452	)			7,179				698
Income before income taxes				22,807			70,413				94,740				157,464
Income tax expense				5,580			12,147				20,036				22,782
Net income				17,227			58,266				74,704				134,682
Income attributable to noncontrolling interest				1,105			174				2,800				1,449
Net income attributable to AdaptHealth Corp.			$	16,122		$	58,092			$	71,904			$	133,233
Weighted average common shares outstanding - basic				134,227			131,684				134,186				124,228
Weighted average common shares outstanding - diluted				137,583			140,322				138,599				133,638
Basic net income per share			$	0.11		$	0.40			$	0.49			$	0.97
Diluted net income per share			$	0.11		$	0.20			$	0.35			$	0.27

ADAPTHEALTH CORP.
Consolidated Statements of Cash Flows (Unaudited)
(in thousands)		Nine Months Ended September 30,
		2022				2021
Cash flows from operating activities:
Net income		$	74,704			$	134,682
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization, including patient equipment depreciation			248,835				180,827
Equity-based compensation			16,784				21,394
Change in fair value of warrant liability			(17,145	)			(57,359	)
Change in fair value of contingent consideration common shares liability			—				(34,050	)
Reduction in the carrying amount of operating lease right-of-use assets			16,924				23,832
Deferred income tax expense			18,058				11,666
Change in fair value of interest rate swaps, net of reclassification adjustment			(2,202	)			(2,185	)
Amortization of deferred financing costs			3,926				4,069
Write-off of deferred financing costs			—				4,054
Loss on extinguishment of debt from prepayment penalty			—				16,135
Other			(2,023	)			(1,614	)
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable			2,357				(25,046	)
Inventory			(3,992	)			3,626
Prepaid and other assets			4,211				(137	)
Operating lease obligations			(16,794	)			(23,292	)
Operating liabilities			(66,696	)			(81,852	)
Net cash provided by operating activities			276,947				174,750
Cash flows from investing activities:
Payments for business acquisitions, net of cash acquired			(16,134	)			(1,417,946	)
Purchases of equipment and other fixed assets			(248,511	)			(139,686	)
Payments for cost method investments			(731	)			(875	)
Net cash used in investing activities			(265,376	)			(1,558,507	)
Cash flows from financing activities:
Proceeds from borrowings on long-term debt and lines of credit			—				1,165,000
Repayments on long-term debt and lines of credit			(15,000	)			(822,271	)
Repayments of finance lease obligations			(14,219	)			(31,043	)
Payments for shares purchased under share repurchase program			(13,992	)			—
Proceeds from the exercise of stock options			1,388				12,140
Proceeds received in connection with employee stock purchase plan			1,616				1,016
Proceeds from the issuance of senior unsecured notes			—				1,100,000
Proceeds from the issuance of Class A Common Stock			—				278,850
Payments for equity issuance costs			—				(13,832	)
Payments of deferred financing costs			—				(29,185	)
Payments for tax withholdings from restricted stock vesting and stock option exercises			(2,690	)			(810	)
Payments of contingent consideration and deferred purchase price from acquisitions			(5,563	)			(22,211	)
Distributions to noncontrolling interests			(2,000	)			(1,070	)
Payments for debt prepayment penalties			—				(16,135	)
Net cash (used in) provided by financing activities			(50,460	)			1,620,449
Net (decrease) increase in cash and cash equivalents			(38,889	)			236,692
Cash and cash equivalents at beginning of period			149,627				99,962
Cash and cash equivalents at end of period		$	110,738			$	336,654

Non-GAAP Financial Measures

This press release presents AdaptHealth’s EBITDA and Adjusted EBITDA for the three and nine months ended September 30, 2022 and 2021.

AdaptHealth defines EBITDA as net income (loss) attributable to AdaptHealth Corp., plus net income (loss) attributable to noncontrolling interests, interest expense, net, income tax expense (benefit), and depreciation and amortization.

AdaptHealth defines Adjusted EBITDA as EBITDA (as defined above), plus loss on extinguishment of debt, equity‑based compensation expense, transaction costs, change in fair value of the contingent consideration common shares liability, change in fair value of the warrant liability, and other non-recurring items of expense or income.

The following unaudited table presents the reconciliation of net income attributable to AdaptHealth Corp. to EBITDA and Adjusted EBITDA for the three and nine months ended September 30, 2022 and 2021:

			Three Months Ended							Nine Months Ended
(in thousands)			September 30,							September 30,
			2022			2021				2022				2021
Net income attributable to AdaptHealth Corp.			$	16,122		$	58,092			$	71,904			$	133,233
Income attributable to noncontrolling interest				1,105			174				2,800				1,449
Interest expense, net				28,521			24,252				78,905				69,584
Income tax expense				5,580			12,147				20,036				22,782
Depreciation and amortization, including patient equipment depreciation				92,331			69,828				248,835				180,827
EBITDA				143,659			164,493				422,480				407,875
Loss on extinguishment of debt (a)				—			8,240				—				20,189
Equity-based compensation expense (b)				5,562			5,365				16,784				21,394
Transaction costs (c)				519			4,616				5,832				44,570
Change in fair value of warrant liability (d)				1,364			(16,737	)			(17,145	)			(57,359	)
Change in fair value of contingent consideration common shares liability (e)				—			(10,006	)			—				(34,050	)
Other non-recurring expense, net (f)				9,059			303				19,863				5,221
Adjusted EBITDA			$	160,163		$	156,274			$	447,814			$	407,840

(a) Represents the write-off of unamortized deferred financing costs and other expenses related to refinancing of debt and prepayment penalties for early debt payoff.

(b) Represents equity-based compensation expense for awards granted to employees and non-employee directors.

(c) Represents transaction costs and expenses related to integration efforts related to acquisitions.

(d) Represents a non-cash charge or gain for the change in the estimated fair value of the warrant liability.

(e) Represents a non-cash gain for the change in the estimated fair value of the contingent consideration common shares liability.

(f) The 2022 year-to-date period consists of $9.0 million of consulting expenses associated with systems implementation activities and post-implementation support services, a $4.5 million expense related to changes in AdaptHealth’s estimated TRA liability, $3.8 million of expenses associated with litigation, claims and settlements, $0.7 million of expenses associated with lease terminations, a $0.8 million loss related to the write-off of an investment, and $1.1 million of net other non-recurring expenses. The 2021 year-to-date period consists of $1.9 million of expenses related to legal and other costs associated with the separation of the Company’s former Co-CEO, $0.9 million of expenses associated with litigation, claims and settlements, $1.6 million of expenses associated with lease terminations, and $0.8 million of net other non-recurring charges.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221108005504/en/

AdaptHealth Corp.

Jason Clemens, CFA

Chief Financial Officer

Anton Hie

Vice President, Investor Relations

IR@adapthealth.com

Source: AdaptHealth Corp.

FAQ

What are AdaptHealth's Q3 2022 financial results?

AdaptHealth reported record net revenue of $756.5 million for Q3 2022, a 15.8% increase from Q3 2021, but net income dropped to $16.1 million.

How much did AdaptHealth repurchase in common stock during Q3 2022?

AdaptHealth repurchased $10.6 million of its common stock in Q3 2022.

What is the updated financial guidance for AdaptHealth in 2022?

AdaptHealth's updated guidance for fiscal year 2022 projects net revenue between $2.950 billion and $3.010 billion.

What was AdaptHealth's adjusted EBITDA for Q3 2022?

Adjusted EBITDA for AdaptHealth in Q3 2022 was $160.2 million, a 2.5% increase from the previous year.

What factors contributed to AdaptHealth's revenue growth?

Revenue growth was attributed to strong demand in home medical equipment and sleep product lines, with CPAP patient set-ups at record levels.